Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

Serum level of interleukin-33 and soluble ST2 and their association with disease activity in patients with Behcet's disease.

Kim DJ, Baek SY, Park MK, Park KS, Lee JH, Park SH, Kim HY, Kwok SK.

J Korean Med Sci. 2013 Aug;28(8):1145-53. doi: 10.3346/jkms.2013.28.8.1145. Epub 2013 Jul 31.

2.

Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus.

Mok MY, Huang FP, Ip WK, Lo Y, Wong FY, Chan EY, Lam KF, Xu D.

Rheumatology (Oxford). 2010 Mar;49(3):520-7. doi: 10.1093/rheumatology/kep402. Epub 2009 Dec 21.

PMID:
20026564
3.

Serum IL-33 levels and skin mRNA expression in Behçet's disease.

Hamzaoui K, Kaabachi W, Fazaa B, Zakraoui L, Mili-Boussen I, Haj-Sassi F.

Clin Exp Rheumatol. 2013 May-Jun;31(3 Suppl 77):6-14. Epub 2013 Mar 4.

PMID:
23464866
4.

Soluble ST2 as a marker of disease activity in systemic juvenile idiopathic arthritis.

Ishikawa S, Shimizu M, Ueno K, Sugimoto N, Yachie A.

Cytokine. 2013 May;62(2):272-7. doi: 10.1016/j.cyto.2013.03.007. Epub 2013 Apr 3.

PMID:
23561929
5.

The levels of soluble ST2 in sera and bullous fluid from patients with bullous pemphigoid.

Wakatabi K, Komine M, Meephansan J, Matsuyama Y, Tsuda H, Tominaga S, Ohtsuki M.

Eur J Dermatol. 2012 May-Jun;22(3):333-6. doi: 10.1684/ejd.2012.1706.

PMID:
22494834
6.

The Interleukin 33/ST2 axis in patients with primary Sjögren syndrome: expression in serum and salivary glands, and the clinical association.

Jung SM, Lee J, Baek SY, Lee JH, Lee J, Park KS, Park SH, Kim HY, Kwok SK.

J Rheumatol. 2015 Feb;42(2):264-71. doi: 10.3899/jrheum.140234. Epub 2014 Dec 15.

PMID:
25512474
7.

Serum levels of alpha-1 acid glycoprotein and pentraxin 3 in patients with Behçet's disease and relationship with disease activity.

Yazmalar L, Batmaz İ, Sula B, Alpaycı M, Aydın F, Türkçü F, Yıldız M, Kaplan İ, Bozkurt M, Dağlı AZ, Burkan YK, Sarıyıldız MA.

Int J Dermatol. 2015 Oct;54(10):e394-400. doi: 10.1111/ijd.12959. Epub 2015 Jul 3.

PMID:
26147939
8.

Characterization of interleukin-33 and soluble ST2 in serum and their association with disease severity in patients with chronic kidney disease.

Bao YS, Na SP, Zhang P, Jia XB, Liu RC, Yu CY, Mu SH, Xie RJ.

J Clin Immunol. 2012 Jun;32(3):587-94. doi: 10.1007/s10875-011-9622-7. Epub 2011 Dec 28.

PMID:
22203232
9.

Elevated serum level of IL-33 and sST2 in patients with ankylosing spondylitis: associated with disease activity and vascular endothelial growth factor.

Li XL, Lin TT, Qi CY, Yuan L, Xia LP, Shen H, Lu J.

J Investig Med. 2013 Jun;61(5):848-51. doi: 10.2310/JIM.0b013e31828deed2.

PMID:
23552178
10.

Serum Interleukin-33 in Behcet's Disease: Its Relation to Disease Activity and Clinical Manifestations.

Fawzy RM, Said EA, Mohamed SM, Fouad NA, Akl EM.

Egypt J Immunol. 2015 Jun;22(2):1-8.

PMID:
28502139
11.

Serum levels of soluble ST2 and interleukin-33 in patients with dermatomyositis and polymyositis.

Yuan L, Yao L, Zhao L, Xia L, Shen H, Lu J.

Clin Exp Rheumatol. 2013 May-Jun;31(3):428-32. Epub 2013 Mar 13.

PMID:
23485578
12.

Serum soluble ST2 is associated with ER-positive breast cancer.

Lu DP, Zhou XY, Yao LT, Liu CG, Ma W, Jin F, Wu YF.

BMC Cancer. 2014 Mar 18;14:198. doi: 10.1186/1471-2407-14-198.

13.

Reduced levels of interleukin 33 and increased levels of soluble ST2 in subjects with amyotrophic lateral sclerosis.

Lin CY, Pfluger CM, Henderson RD, McCombe PA.

J Neuroimmunol. 2012 Aug 15;249(1-2):93-5. doi: 10.1016/j.jneuroim.2012.05.001. Epub 2012 May 24.

PMID:
22633272
14.

Potential contribution of interleukin-33 to the development of interstitial lung disease in patients with primary Sjogren's Syndrome.

Zhao L, Yao L, Yuan L, Xia L, Shen H, Lu J.

Cytokine. 2013 Oct;64(1):22-4. doi: 10.1016/j.cyto.2013.07.006. Epub 2013 Jul 31.

PMID:
23910012
15.

Soluble ST2 and interleukin-33 levels in coronary artery disease: relation to disease activity and adverse outcome.

Demyanets S, Speidl WS, Tentzeris I, Jarai R, Katsaros KM, Farhan S, Krychtiuk KA, Wonnerth A, Weiss TW, Huber K, Wojta J.

PLoS One. 2014 Apr 21;9(4):e95055. doi: 10.1371/journal.pone.0095055. eCollection 2014.

16.

Soluble ST2: a new and promising activity marker in ulcerative colitis.

Díaz-Jiménez D, Núñez LE, Beltrán CJ, Candia E, Suazo C, Alvarez-Lobos M, González MJ, Hermoso MA, Quera R.

World J Gastroenterol. 2011 May 7;17(17):2181-90. doi: 10.3748/wjg.v17.i17.2181.

17.

Measurement of interleukin-33 (IL-33) and IL-33 receptors (sST2 and ST2L) in patients with rheumatoid arthritis.

Hong YS, Moon SJ, Joo YB, Jeon CH, Cho ML, Ju JH, Oh HJ, Heo YJ, Park SH, Kim HY, Min JK.

J Korean Med Sci. 2011 Sep;26(9):1132-9. doi: 10.3346/jkms.2011.26.9.1132. Epub 2011 Sep 1.

18.

ST2 and IL-33 in pregnancy and pre-eclampsia.

Granne I, Southcombe JH, Snider JV, Tannetta DS, Child T, Redman CW, Sargent IL.

PLoS One. 2011;6(9):e24463. doi: 10.1371/journal.pone.0024463. Epub 2011 Sep 16.

19.

Correlation between soluble triggering receptor expressed on myeloid cells-1 and endoscopic activity in intestinal Behçet's disease.

Lee HJ, Shin HS, Jang HW, Kim SW, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH.

Yonsei Med J. 2014 Jul;55(4):960-6. doi: 10.3349/ymj.2014.55.4.960.

20.

Significance of serum interleukin-8 levels in patients with Behcet's disease: high levels may indicate vascular involvement.

Durmazlar SP, Ulkar GB, Eskioglu F, Tatlican S, Mert A, Akgul A.

Int J Dermatol. 2009 Mar;48(3):259-64. doi: 10.1111/j.1365-4632.2009.03905.x.

PMID:
19261013

Supplemental Content

Support Center